Noora (Vaccine)

Noora (vaccine)
Vaccine description
Target disease	SARS-CoV-2
Type	Protein subunit
Clinical data
Routes of; administration	Intramuscular

Short description: Vaccine candidate against COVID-19

Noora (Persian: نورا) is a COVID-19 vaccine candidate developed by Baqiyatallah University of Medical Sciences in collaboration with Plasma Darman Sarv Sepid Co. (lit. White Cypress Plasma Treatment) in Iran.^[1]^[2]

Medical uses

It requires three doses given by intramuscular injection on days 0, 21 and 35.^[3]

Pharmacology

Noora is a recombinant RBD protein subunit vaccine.^[3]

Manufacturing

Up to 8 December 2021, 5 millions doses have been produced.^[4]

Clinical trials

Clinical trials of Noora
Phase	Registration number	Start	Number of participants			Age of participants	Ref
Phase	Registration number	Start	Total	Vaccine	Placebo	Age of participants	Ref
I	IRCT20210620051639N1	25 June 2021	70	30 (80 µg) 30 (120 µg)	10 (placebo)	18–50 years	^[3]
II	IRCT20210620051639N2	10 October 2021	300	240	60	18–40 years	^[5]
III	IRCT20210620051639N3	23 December 2021	10000			>18 years	^[6]

References

↑ "IRGC starts clinical trial of "Noora" coronavirus vaccine". Tehran Times. 27 June 2021. https://www.tehrantimes.com/news/462470/IRGC-starts-clinical-trial-of-Noora-coronavirus-vaccine.
↑ "IRGC Commander: Iran-Made 'Noora' Coronavirus Vaccine Ready for 2nd Stage of Human Trial". Fars News Agency. 22 August 2021. https://www.farsnews.ir/en/news/14000531000599/IRGC-Cmmander-Iran-Made-‘Nra’-Crnavirs-Vaccine-Ready-fr-2nd-Sage-f.
↑ ^3.0 ^3.1 ^3.2 "A randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of three dose regimens of COVID-19 RBD protein recombinant vaccine (AmitisGen; 80µg and 120µg) in a healthy population". Iranian Clinical Trials Registry. 25 June 2021. IRCT20210620051639N1. Retrieved 1 July 2021.
↑ "5 میلیون دوز واکسن "نورا" تولید شد- اخبار پزشکی - اخبار اجتماعی تسنیم | Tasnim" (in fa). https://www.tasnimnews.com/fa/news/1400/09/17/2622286/5-میلیون-دوز-واکسن-نورا-تولید-شد.
↑ "IRCT | A double-blind, randomized, placebo-controlled Phase II clinical trial to evaluate the immunogenicity and safety of covid-19 recombinant RBD protein vaccine (80 microgram) of Plasma Darman Sarve Sepid Co. in healthy population.". https://en.irct.ir/trial/59156.
↑ "IRCT |Phase 3 Clinical Trial to evaluate the Immunogenicity and Safety of Covid19 Recombinant RBD Protein Vaccine (Noora Vaccine) as a Booster Vaccine after injection of existing Vaccines in IRAN". https://en.irct.ir/trial/60796.

0.00

(0 votes)

[1] "IRGC starts clinical trial of "Noora" coronavirus vaccine". Tehran Times. 27 June 2021. https://www.tehrantimes.com/news/462470/IRGC-starts-clinical-trial-of-Noora-coronavirus-vaccine.

[2] "IRGC Commander: Iran-Made 'Noora' Coronavirus Vaccine Ready for 2nd Stage of Human Trial". Fars News Agency. 22 August 2021. https://www.farsnews.ir/en/news/14000531000599/IRGC-Cmmander-Iran-Made-‘Nra’-Crnavirs-Vaccine-Ready-fr-2nd-Sage-f.

[:0-3] 3.0 ^3.1 ^3.2 "A randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of three dose regimens of COVID-19 RBD protein recombinant vaccine (AmitisGen; 80µg and 120µg) in a healthy population". Iranian Clinical Trials Registry. 25 June 2021. IRCT20210620051639N1. Retrieved 1 July 2021.

[4] "5 میلیون دوز واکسن "نورا" تولید شد- اخبار پزشکی - اخبار اجتماعی تسنیم | Tasnim" (in fa). https://www.tasnimnews.com/fa/news/1400/09/17/2622286/5-میلیون-دوز-واکسن-نورا-تولید-شد.

[5] "IRCT | A double-blind, randomized, placebo-controlled Phase II clinical trial to evaluate the immunogenicity and safety of covid-19 recombinant RBD protein vaccine (80 microgram) of Plasma Darman Sarve Sepid Co. in healthy population.". https://en.irct.ir/trial/59156.

[6] "IRCT |Phase 3 Clinical Trial to evaluate the Immunogenicity and Safety of Covid19 Recombinant RBD Protein Vaccine (Noora Vaccine) as a Booster Vaccine after injection of existing Vaccines in IRAN". https://en.irct.ir/trial/60796.